Page last updated: 2024-10-24

Peyer's patch development

Definition

Target type: biologicalprocess

The process whose specific outcome is the progression of Peyer's patches over time, from their formation to the mature structure. Peyer's patches are typically found as nodules associated with gut epithelium with distinct internal structures including B- and T-zones for the activation of lymphocytes. [GOC:add, ISBN:0781735149]

Peyer's patches, specialized lymphoid tissues within the small intestine, develop through a complex process involving interactions between epithelial cells, mesenchymal cells, and immune cells. This development begins during fetal life and continues postnatally, ensuring the proper formation and functionality of these critical immune structures.

**1. Induction and Patterning:**

* The initial step involves the induction of Peyer's patch formation by signals from the underlying mesenchyme, specifically the stromal cells expressing the transcription factor, **Lef1**.
* This induction leads to the formation of **crypt-like invaginations** in the intestinal epithelium, which are the precursors of Peyer's patches.
* These invaginations are characterized by a **distinctive epithelial cell population** called **M cells** (microfold cells), which play a crucial role in antigen sampling and delivery to the immune cells within the Peyer's patches.
* The patterning of these structures is further influenced by **Wnt signaling**, which plays a role in crypt formation and epithelial cell differentiation.

**2. Lymphoid Cell Recruitment and Expansion:**

* As the invaginations develop, they attract and recruit lymphoid cells from the surrounding mesenchyme and the bloodstream.
* These lymphoid cells include **B cells, T cells, and dendritic cells**, which are essential for adaptive immune responses.
* Within the developing Peyer's patch, these cells undergo proliferation and differentiation, forming the characteristic **lymphoid follicles** and **T cell zones**.
* This process is regulated by various factors, including **cytokines**, such as IL-7, and **chemokines**, which attract specific immune cell populations.

**3. Functional Maturation:**

* The final stages of Peyer's patch development involve the acquisition of full functional capacity, including the ability to mount effective immune responses against ingested antigens.
* This maturation process is characterized by the establishment of a **specialized microenvironment** within the Peyer's patch, which promotes the generation of **memory T cells** and **antibody-producing B cells**.
* The **M cells** continue to play a crucial role by sampling antigens from the intestinal lumen and delivering them to the immune cells within the Peyer's patch.

**4. Maintenance and Homeostasis:**

* Once fully formed, Peyer's patches are maintained throughout life by a balance of cell proliferation, differentiation, and apoptosis.
* This dynamic equilibrium ensures the continued functionality of these structures in the face of constant exposure to dietary antigens and potential pathogens.

**5. Importance in Gut Immunity:**

* Peyer's patches play a critical role in the development and maintenance of gut immunity, particularly in the defense against enteric pathogens.
* They provide a site for antigen sampling, immune cell activation, and the generation of memory immune cells, which are essential for rapid and effective responses to subsequent infections.

The development of Peyer's patches is a complex and tightly regulated process involving multiple cell types and signaling pathways. These structures are essential for maintaining gut homeostasis and providing protection against pathogens, highlighting their crucial role in overall health.'
```"

Proteins (3)

ProteinDefinitionTaxonomy
Signal transducer and activator of transcription 5BA signal transducer and activator of transcription 5b that is encoded in the genome of human. [PRO:WCB, UniProtKB:P51692]Homo sapiens (human)
Adenosine deaminaseAn adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813]Homo sapiens (human)
Voltage-dependent L-type calcium channel subunit beta-4A voltage-dependent L-type calcium channel subunit beta-4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O00305]Homo sapiens (human)

Compounds (15)

CompoundDefinitionClassesRoles
tacrinetacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.

Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
acridines;
aromatic amine
EC 3.1.1.7 (acetylcholinesterase) inhibitor
9-(2-hydroxy-3-nonyl)adenine9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase
nimodipinenimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
2-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester
antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
suramin sodiumsuramin sodium : An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness.organic sodium saltangiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
coformycincoformycinsEC 3.5.4.4 (adenosine deaminase) inhibitor
adenosinequinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlitadenosines;
purines D-ribonucleoside
analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
nebularinenebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage.

nebularine: structure
purine ribonucleoside;
purines D-ribonucleoside
fungal metabolite
9-(2-hydroxy-3-nonyl)adenine(2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase.EHNAEC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor
9-(2-hydroxy-3-nonyl)adenine(2S,3R)-EHNA : EHNA of absolute configuration 2S,3R.EHNA
1-deazaadenosine1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source
pentostatinpentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.

Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
nf 449
ith 4012
8-azanebularine8-azanebularine: structure in first source
msh, 4-nle-7-phe-alpha-polypeptidedermatologic drug